ClinicalTrials.gg
Not yet recruitingNCT07935941Updated Nov 13, 2026

A Phase I Study of HLX109 in Healthy Participants

A Phase 1 interventional study of HLX109 and HLX109 in First in Man Study to Evaluate Initial Safety, sponsored by Shanghai Henlius Biotech. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a randomized, double-Blind, single ascending dose, phase I clinical study to evaluate safety, tolerability and pharmacokinetic profiles of HLX109 in healthy participants

Read the detailed description

This first-in-human clinical trial of HLX109 is a randomized, double-blind, placebo-controlled, single ascending dose phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX109 in healthy adult participants. Each participant is expected to participate in the study for 112 days. The first 28 days constitute the screening period, followed by a study drug administration and an 84-day follow-up period.

02

Conditions studied

  • First in Man Study to Evaluate Initial Safety
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participates in the clinical study, with a full understanding of the study procedures; provides written by signing and dating the informed consent form (ICF); and is willing and able to comply with all protocol-specified requirements and follow-up visits.
  2. Adult male or female, aged 18 (inclusive) to 55 years (inclusive) at the time of ICF signing.
  3. (BMI) between 18.5 (inclusive) and 28.0 (exclusive) kg/m2 at screening.
  4. No abnormalities in medical history or clinical evaluations (including physical examination, clinical laboratory assessments, diagnostic imaging, vital signs, and 12-lead ) at screening. At the investigator's discretion, screening assessments may be repeated to confirm eligibility, provided that all assessments are completed within the defined screening window.
  5. A female participant must be of no , , or premenopausal with one of the following records: hysterectomy, tubal ligation, or bilateral salpingectomy. The heterosexual partners of all participants and the participants must agree to take measures during the treatment period and at least 3 months after the last dose of IMP. (Appendix 2.)
  6. Prior to randomization, complete all age-appropriate vaccinations according to current immunization guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. With sunburn, scar tissue, tattoos (more than 25% of body area), open sores, or branding at screening that, in the opinion of the investigator, would interfere with the assessment of adverse skin reactions.
  3. History of or allergic reactions to two or more medications, or known hypersensitivity to IMP or any of its , or a history of anaphylaxis. Additionally, individuals with a history of multiple and/or severe allergic manifestations (including food allergies) are excluded. (Note: Prospective participants with seasonal allergic rhinitis/allergies are eligible for enrollment, provided they are currently asymptomatic or their symptoms are well-controlled).
  4. History of venous thromboembolic events and/or has a first-degree relative with an idiopathic venous thromboembolic event.
  5. History or evidence of substance or alcohol abuse, defined as follows:

    • A history of substance abuse within 1 year prior to screening, or a positive urine drug screen at the screening.
    • A history of alcohol abuse within 6 months prior to screening, or a positive breath alcohol test at the screening.
  6. History of the following diseases with a clear diagnosis within 6 months prior to screening: cardiovascular diseases, hematological diseases, respiratory diseases, gastrointestinal diseases, hepatic impairment, renal impairment (e.g. less than 75 mL/min/1.73m²), endocrine, metabolic, neurological, psychiatric, dermatological, musculoskeletal, or immunological disorders. Participants will also be excluded if they present with any other concurrent medical condition that, in the judgment of the investigator, may confound the interpretation of the study data or compromise participant safety.
  7. History of hemorrhagic diathesis (including but not limited to non-traumatic bleeding) within 6 months before screening or diagnosed diseases that increase hemorrhagic diathesis.
  8. or increased risk of malignancy prior to screening: suspected and/or diagnosed with any malignancy (except for basal cell carcinoma, squamous cell carcinoma of skin in situ, or cervical carcinoma in situ occurring within 5 years prior to screening with no evidence of recurrence after treatment).
  9. Major surgery (including procedures under general anesthesia) within 3 months prior to screening or organ transplantation prior to screening. Or still in the state of disease, trauma, or incomplete recovery after surgery at screening (significant changes in organ function, or significantly limited ability to live and work compared with that before disease, trauma, or surgery, or requiring continuous rehabilitation treatment), or planning to undergo surgery during the study.
  10. Chronic or recurrent infection at screening, systemic or local severe infection requiring hospitalization or intravenous injection of antibiotics within 1 month before screening, or history of acute infection within 14 days before screening.
  11. Any severe herpes infection at any time prior to before screening, but not limited to, disseminated herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years prior to Screening), or ophthalmic herpes (ever).
  12. Any condition requires medication and/or other treatments at screening.
  13. Evidence of active or prior tuberculosis (TB) infection on lung imaging during the screening period.
  14. Abnormalities in 12-lead at screening or admission, such as (QTc) interval > 450 ms in males and > 470 ms in females (Fridericia's method).
  15. Abnormal results of the following Laboratory assessments at screening or admission:

    • > 1.1 × (ULN), or Hemoglobin \< 0.9× lower limit of normal (LLN)
    • count > 1.1 ×ULN, or Platelet count \< 0.9× LLN
    • \< 1.5 × 109/L.
    • Alkaline phosphatase (ALP) > 1.5 × ULN, or total (TBIL) > 1.5 × ULN, or (ALT) > 1.5 × ULN, or aspartate aminotransferase (AST) > 1.5 × ULN, or AST/ALT between 1-1.5 × ULN (inclusive) and considered clinically significant by the investigator, or blood amylase > 1 × ULN.
    • (INR) > 1.5.
    • Blood thyroid-stimulating hormone (TSH) \< 1×LLN, or TSH > 1 ×ULN.
    • Estimated glomerular filtration rate (eGFR) \< 75mL/min/1.73 m2, or urine protein qualitative≥2+
    • Positive interferon-γ release assay.
    • Positive serology for (HIV) antibody, Virus surface antigen (HBsAg), or Virus (HCV) antibody; or a positive treponemal test for syphilis.
  16. Have participated in a clinical study of other products before screening, with an interval between this study and the previous study being too short: within 1 month before the first dose of this study or within 5 half-lives of the previous investigational product (whichever is longer). Or plan to participate in clinical studies of other investigational products before completing all scheduled assessments in this clinical study. Participants who violate the restrictions on concomitant medications (Appendix 6) should be excluded.
  17. Have participated in surgical or device clinical studies within 3 months prior to screening, or are currently participating in other surgical or device clinical studies, or plan to participate in other surgical or device clinical studies during this study.
  18. Receipt of any vaccine within 14 days prior to randomization or planned receipt of any vaccine during the study.
  19. Unable to follow the lifestyle restrictions (Appendix 3) during the study.
  20. Prescription and over the counter (OTC) drugs, herbal medicines, vitamins, minerals, or oral iron supplements (Appendix 3) not approved by the investigator during the study.
  21. Unable or unwilling to undergo repeated venipuncture due to poor tolerance or difficulty in finding a vein, or with a history of fear of blood or needles.
  22. Donated whole blood or blood components (more than 400 mL) or lost a large amount of blood (more than 400 mL) within 2 months prior to IMP administration , or plan to donate whole blood or blood components during the study.
  23. The participant has a hierarchical or dependent relationship with the investigator or the study site (including employees and their immediate family members), or has any other condition that, as determined by the investigator, renders the participants unsuitable for participation or places their rights and well-being at risk.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    HLX109

    Dose Escalation

    Drug: HLX109

  • Placebo comparator
    Placebo

    Dose Escalation

    Drug: Placebo

Interventions

  • DrugHLX109

    HLX109: A mg, SC, single dose

  • DrugHLX109

    HLX109: B mg, SC, single dose

  • DrugHLX109

    HLX109: C mg, SC, single dose

  • DrugHLX109

    HLX109: D mg, SC, single dose

  • DrugHLX109

    HLX109: E mg, SC, single dose

  • DrugHLX109

    HLX109: F mg, SC, single dose

  • DrugHLX109

    HLX109: G mg, SC, single dose

  • DrugPlacebo

    Placebo: A mg, SC, single dose

  • DrugPlacebo

    HLX109: B mg, SC, single dose

  • DrugPlacebo

    HLX109: C mg, SC, single dose

  • DrugPlacebo

    HLX109: D mg, SC, single dose

  • DrugPlacebo

    HLX109: E mg, SC, single dose

  • DrugPlacebo

    HLX109: F mg, SC, single dose

  • DrugPlacebo

    HLX109: G mg, SC, single dose

06

What researchers measure

Primary outcomes

  1. Safety: number and percentage of participants with adverse events (AEs) assessed by CTCAE v6.0

    Time frame: Up to approximately 84 days

  2. Safety: number and percentage of participants with serious adverse events (SAEs) assessed by CTCAE v6.0

    Time frame: Up to approximately 84 days

  3. Safety: number and percentage of participants with adverse events of special interest (AESIs) assessed by CTCAE v6.0

    Time frame: Up to approximately 84 days

  4. Safety: number and percentage of participants with laboratory abnormalities

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein); urinalysis (decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy\[if urine tested positive for blood, protein, nitrites or leukocyte esterase\]. Laboratory abnormalities were assessed based on values outside the reference range and/or judged clinically significant by the investigator according to NCI CTCAE Version 6.0.

    Time frame: Up to approximately 84 days

  5. Safety: number and percentage of participants with notable 12-Lead electrocardiogram (ECG) values

    Criteria for notable ECG values were as follow: corrected QT interval by Fredericia formula (QTcF) in msec new(newly occurring post-baseline value) \> 500, or increase from baseline \>60.

    Time frame: Up to approximately 84 days

  6. Safety: number and percentage of participants with clinically notable vital signs

    Criteria for notable vital signs: Pulse rate \<40 beats per minute (bpm) to \>120 bpm, Diastolic blood pressure \< 50 millimeter of mercury (mmHg), systolic blood pressure \< 90 mmHg.

    Time frame: Up to approximately 84 days

Secondary outcomes

  1. PK: peak concentration (Cmax)

    Time frame: Up to approximately 84 days

  2. PK: area under the concentration-time curve (AUC0-t, AUC0-inf)

    Time frame: Up to approximately 84 days

  3. PK: time to peak concentration (Tmax)

    Time frame: Up to approximately 84 days

  4. PK: terminal elimination half-life (t1/2)

    Time frame: Up to approximately 84 days

  5. PK: apparent clearance (CL/F)

    Time frame: Up to approximately 84 days

  6. PK: apparent volume of distribution (Vz/F)

    Time frame: Up to approximately 84 days

  7. PK: mean residence time (MRT)

    Time frame: Up to approximately 84 days

  8. PK: percentage of extrapolated AUC (%AUCex)

    Time frame: Up to approximately 84 days

  9. Immunogenicity: incidence of anti-drug antibody (ADA) against HLX109 and recombinant human hyaluronidase.

    Time frame: Up to approximately 84 days

  10. Immunogenicity: incidence of neutralizing antibody (NAb) against HLX109 and recombinant human hyaluronidase.

    Time frame: Up to approximately 84 days

  11. Exploratory: serum free/total soluble IL-1RAP (sIL-1RAP) levels

    Time frame: Up to approximately 84 days

  12. Exploratory: ex vivo stimulated cytokine release levels in whole peripheral blood

    Time frame: Up to approximately 84 days

  13. Exploratory: IL-1RAP receptor occupancy (RO)

    Time frame: Up to approximately 84 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Sep 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2026
First posted
Nov 13, 2026
StartEst.
Nov 18, 2026
Primary completionEst.
Sep 20, 2027
CompletionEst.
Nov 20, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935941
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Nov 18, 2026 (estimated)
Primary completion
Sep 20, 2027 (estimated)
Completion
Nov 20, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Wai Han Ho
Contact
Waihan_Ho@henlius.com
+65-96253244

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion